Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
288
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Sangmin LeeDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
View further author information
,
Pinkal DesaiDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Bianca EdirisingheDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Samantha PianelloDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Tania CurcioDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Michael SamuelDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
,
Ellen K. RitchieDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
&
Gail J. RobozDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAView further author information
 show all
Pages 498-500 | Received 13 May 2020, Accepted 29 Sep 2020, Published online: 10 Oct 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

S. Lee has received research funding from LAM Therapeutics and consulting fees from AstraZeneca, Helsinn, Jazz, Karyopharm, Pharmerit, and Roche Molecular Systems. P. Desai has received research funding from Astex Therapeutics, and consulting fees from Astellas, Cellerant, Celgene, and Agios. E.K. Ritchie has received research funding from Jazz and Pfizer, and consulting fees from Celgene, Novartis, Incyte, Agios, and Roche/Genentech. G.J. Roboz has received research funding from Cellectis and consulting fees from Abbvie, Actinium, Agios, Amphivena, Argenix, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jasper Therapeutics, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, Trovagene.

Additional information

Funding

This study was funded by CTI BioPharma Corp.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.